Hasil Pencarian  ::  Simpan CSV :: Kembali

"Penelitian ini bertujuan mencari penanda respons tumor yang lebih dini untuk kemoterapi neoajuvan pada kasus kanker payudara stadium lanjut, yaitu dengan mengkorelasikan derajat kemiringan washout fase delay kurva kinetik pada pemeriksaan DCE-MRI dengan perubahan ukuran tumor kanker payudara. Perubahan neovaskularisasi sudah dapat dinilai sejak 24 jam pertama setelah pemberian kemoterapi siklus pertama, sedangkan pengukuran tumor umumnya paling baik dinilai setelah kemoterapi neoajuvan siklus ketiga. Penelitian ini merupakan studi deskriptif analitik dari data sekunder MRI payudara mulai Agustus 2011 hingga April 2013. Analisa korelasi perubahan derajat kemiringan washout fase delay kurva kinetik DCE-MRI dengan perubahan ukuran tumor sebelum dan sesudah pemberian kemoterapi neoajuvan awal, dilakukan dengan uji korelasi Pearson. Hasil analisa menunjukkan tidak ada korelasi yang bermakna (r=0,151, p=0,622) antara perubahan sudut kemiringan washout fase delay kurva kinetik dengan perubahan ukuran tumor sebelum dan setelah pemberian kemoterapi neoajuvan, sehingga dapat disimpulkan bahwa parameter perubahan sudut kemiringan washout secara tunggal tidak dapat berfungsi sebagai penanda respons tumor kemoterapi neoajuvan. Hal ini dikarenakan respons tumor merupakan proses yang mutifaktorial sehingga perubahan sudut gradien washout saja secara langsung tidak dapat menunjukkan respons yang terjadi pasca kemoterapi neoajuvan.

---

This study assessed the possibility of a faster tumor response marker for neoadjuvant chemotherapy (NAC) by correlating the changes in kinetic curve washout gradient degree on the delayed phase of DCE-MRI after the first cycle, with changes in tumor size after the third cycle, as well as their roles in assessing tumor response for NAC. Studies show that changes in tumor size after the third NAC can be used to detect tumor response, whereas neovascularization changes with DCE-MRI can be detected as fast as 24 hours after the first cycle of chemotherapy.

This is an analytic study using breast MR data obtained between August 2011 until April 2013. Analysis of the correlation between changes in kinetic curve washout gradient with changes in tumor size before and after NAC was performed using the Pearson correlation test.

Based on the correlation analysis results, there is no significant correlation (r=0,151, p=0.622) btween the change in the angle of the washout kinetic curve gradient with the changes in tumor size before and after NAC. This concludes that changes in the degree of the washout angle alone cannot serve as a marker of tumor response to NAC, due of the multifactorial variables that take part in the process, and the kinetic curve alone is not sufficient to directly evaluate response."

"Tujuan: Penelitian ini dilakukan untuk mengetahui korelasi perubahan nilai ADC pada DWMRI dengan perubahan ukuran tumor pasca kemoterapi neoajuvan kanker payudara dalam menilai respons kemoterapi neoajuvan. Metode: Penelitian studi deskriptif analitik dari data sekunder MRI pasien kanker payudara yang mendapat kemoterapi neoajuvan serta menjalankan pemeriksaan MRI. Pemeriksaan MRI dilakukan sebelum pasien mendapat kemoterapi neoajuvan, setelah pasien mendapat kemoterapi neoajuvan siklus pertama dan siklus ketiga. Pengukuran ukuran tumor dilakukan sesuai standar RECIST, sedangkan nilai ADC diperoleh pada nilai b800s/mm2. Hasil dan diskusi: Dilakukan analisis bivariat dengan menggunakan korelasi Pearson untuk melihat korelasi perubahan nilai ADC kedua terhadap nilai ADC pertama dengan perubahan ukuran tumor pada pemeriksaan MRI ketiga terhadap pemeriksaan MRI pertama. Sebanyak 17 pasien penelitian dengan usia antara 40 tahun sampai 65 tahun dan ukuran tumor antara 5,41 cm sampai 13,41 cm. Terdapat 16 pasien yang mengalami peningkatan nilai ADC dan 1 pasien yang mengalami penurunan nilai ADC setelah pemberian kemoterapi neoajuvan siklus pertama. Sebanyak 17 pasien mengalami pengurangan ukuran tumor setelah kemoterapi neoajuvan siklus ketiga. Berdasarkan standar RECIST diperoleh sebanyak 7 pasien dengan pengurangan ukuran tumor lebih dari 30% (antara 31,55% sampai 56,25%) dan sebanyak 10 pasien dengan pengurangan ukuran tumor kurang dari 30% (antara 7,47% sampai 29,22%). Nilai korelasi yang diperoleh sebesar -0,499. Kesimpulan: Terdapat korelasi yang bermakna antara perubahan nilai ADC pada DWMRI dengan perubahan ukuran tumor sebagai respons kemoterapi neoajuvan kanker payudara dengan kekuatan korelasi yang sedang dan arah negatif.

---

Objectives: To determine the correlation of changes in ADC values in DWMRI with changes in tumor size after neoadjuvant chemotherapy in breast cancer to assess neoadjuvant chemotherapy response.

Methods: Analytical descriptive study using secondary data from MRI of breast cancer patients receiving neoadjuvant chemotherapy as well as running an MRI. MRI examination performed before neoadjuvant chemotherapy, after received first cycle neoadjuvant chemotherapy and third cycle. Tumor size measurements carried out according to standard RECIST, whereas the ADC values obtained in the b800s/mm2. Bivariate analysis using Pearson correlation was conducted to determine the correlation of changes in the value of the second ADC to first ADC and changes of the tumor size on the third MRI to the first MRI examination.

Result and discussion: A total of 17 study patients, 40 years to 65 years old, tumor size between 5.41 cm to 13.41 cm. 16 patients experienced an increase in ADC values while 1 patient had decreased ADC values after the first cycle of neoadjuvant chemotherapy. Tumor size in all patients decreased after three cycles of neoadjuvant chemotherapy. Based on RECIST standards, 7 patients showed tumor size reduction of more than 30% (between 31.55% to 56.25%) and tumor size in 10 patients was reduced less than 30% (between 7.47% to 29.22% ). Correlation value of -0.499 obtained.

Conclusions: There is a significant moderate and negative correlation between in ADC value changes in DWMRI with tumor size changes in response to neoadjuvant chemotherapy."

"Latar belakang: Osteosarkoma adalah tumor tulang ganas yang paling banyak terjadi pada anak dan remaja. Kemoterapi neoadjuvan dapat meningkatkan kesintasan 5 tahun hingga 60 – 80% pada pasien osteosarkoma. Baku emas evaluasi respon kemoterapi neoadjuvan adalah histological mapping untuk menilai persentase nekrosis tumor. Volumetri-Magnetic Resonance Imaging (MRI) menggunakan 3D Slicer dapat menilai nekrosis tumor, tumor viabel, dan volume tumor total secara kuantitatif. Tujuan: Menganalisa korelasi volume dan persentase tumor viabel berdasarkan volumetri-MRI dengan nilai persentase tumor viabel berdasarkan pemeriksaan histopatologi pada pasien osteosarkoma pasca kemoterapi neoadjuvan. Metode: Melakukan volumetri tumor pada MRI pasca kemoterapi neoadjuvan dengan menggunakan teknik segmentasi manual dan semiotomatis pada 3D Slicer untuk mendapatkan volume total tumor, area nekrosis, serta tumor viabel. Hasil pengukuran volumetri tumor viabel dan persentase tumor viabel pasca kemoterapi dikorelasikan dengan persentase tumor viabel berdasarkan histopatologi. Analisis dilakukan dengan uji Spearman. Hasil: Pada 31 subyek penelitian, nilai median persentase tumor viabel berdasarkan volumetri-MRI yaitu 65,9% (range 19,7 – 99,5%), sedangkan berdasarkan pemeriksaan histopatologi didapatkan nilai median 53% (range 8 – 100%). Persentase tumor viabel berdasarkan volumetri-MRI tidak berkorelasi signifikan (p>0,05) dengan persentase tumor viabel berdasarkan histopatologi dengan nilai R: 0,333. Kesimpulan: Terdapat kecenderungan berbanding lurus antara persentase tumor viabel berdasarkan volumetri-MRI dan pemeriksaan histopatologi, walaupun tidak terdapat korelasi yang signifikan.

---

Background: Osteosarcoma is the most common malignant bone tumor in children and adolescents. Neoadjuvant chemotherapy can improve 5-year survival up to 60 - 80% in osteosarcoma patients. The gold standard of neoadjuvant chemotherapy response evaluation is histological mapping to determine the percentage value of tumor necrosis. 3D Slicer volumetry based on Magnetic Resonance Imaging (MRI) can quantitatively assess tumor necrosis, viable tumor, and total tumor volume. Objective: Analyze the correlation between volume and percentage of viable tumors based on MRI-volumetry and histopathological in osteosarcoma patients post neoadjuvant-chemotherapy. Methods: Perform tumor volumetry on MRI post neoadjuvant-chemotherapy using manual and semiautomatic segmentation techniques on 3D Slicer to obtain total tumor volume, necrosis area, and viable tumor. The results of volumetric measurement of viable tumor and the percentage of viable tumor post chemotherapy were correlated with the percentage of viable tumor from histopathological examination. Analysis was performed with Spearman's test. Results: Based on 31 study subjects, the median percentage of viable tumors based on MRI-volumetry was 65.9% (range: 19.7 - 99.5%), while based on histopathology, the median value was 53% (range: 8 - 100%). The percentage of viable tumors based on MRI-volumetry was not significantly correlated (p>0.05) with the percentage of viable tumors based on histopathology with an R value: 0.333. Conclusion: There is a directly proportional trend between the percentage of viable tumors based on MRI-volumetry and histopathological examination, although there was no significant correlation."

"[ABSTRAKLatar belakang: Respons tumor setelah pemberian sitostatik sebagai kemoterapi neoajuvan pada pasien kanker payudara masih belum memuaskan dan respons tumor baru dapat dinilai setelah siklus ke-3; untuk mengurangi efek samping sitostatik dan penghematan biaya bagi yang tidak respons dibutuhkan faktor prediksi respons tumor lebih awal.Tujuan penelitian: Untuk mengetahui apakah perubahan rasio choline/water pada pemeriksaan magnetic resonance spectroscopy (MRS) dapat digunakan sebagai faktor prediksi awal respons tumor pasien kanker payudara yang memperoleh sitostatik sebagai kemoterapi neoajuvan dan menganalisis korelasi persentase perubahan rasio choline/water eksternal dengan internal.Bahan dan cara: Penelitian dilaksanakan di Rumah Sakit Umum Pusat Nasional Cipto Mangunkusumo (RSCM) pada bulan Agustus 2011 sampai April 2014. Subjek memperoleh sitostatik sebagai kemoterapi neoajuvan. Pemeriksaan MRI/MRS 1,5 T dilakukan sebelum sitostatik I, 20 atau 21 hari setelah sitostatik I dan setelah sitostatik III, menggunakan program syngo-GRACE untuk MRS. Tumor diukur berdasarkan RECIST 1.1. Respons tumor ≥ 30% dinyatakan positif, dan < 30% dinyatakan negatif. Hasil: Diperoleh 40 subjek dengan kanker payudara ukuran tumor ≥ 5 cm tanpa ulkus respons tumor positif 47,5%, peningkatan rasio choline/water eksternal 35% dan choline/water internal 42,5%. Peningkatan rasio choline/water eksternal pada MRS I- MRS II pada hari ke-20 atau ke-21 setelah pemberian sitostatik 1 menunjukkan respons tumor positif, RR=0,49 (IK 0,26-0,90) terutama untuk stadium < IIIC. Pada peningkatan rasio choline/water internal RR=0,54 (IK 0,28-1,04) dan penurunan nilai Apparent Diffusion Coefficient (ADC) RR= 0,51 (IK 0,23-1,13), didapatkan hubungan yang sama tetapi lebih lemah. Didapatkan pula korelasi sedang arah positif antara persentase perubahan rasio choline/water eksternal dengan persentase perubahan rasio choline/water internal (r=0,572, p=0,000). Derajat keganasan, Ki67, Bcl2 dan MVD tidak dapat digunakan sebagai faktor prediksi respons tumor. Pada Ki67 sama dengan atau lebih dari 14%, masih diperoleh repons tumor positif sedangkan pada Ki67 kurang dari 14%, tidak ditemukan respon tumor positif.Simpulan: Peningkatan rasio choline/water eksternal pada MRS I-MRS II pada hari ke-20 atau ke-21 setelah pemberian sitostatik 1 sebagai kemoterapi neoajuvan dapat memprediksi pengecilan tumor setelah sitostatik III sama dengan atau lebih besar dari 30% terutama untuk stadium < IIIC. Perubahan rasio choline/water eksternal dan internal dapat digunakan untuk memprediksi respons tumor setelah pemberian sitostatik.;

---

ABSTRACTBackground : Cytostatics administration as neoadjuvant chemotherapy does not provided satisfactory tumor response in breast cancer patients and could be asses after 3rd cycle. To minimize the side effects and cost of cytostatics, early predictive factor of tumor response following neoadjuvant therapy in breast cancer patients is required. Objectives: The purpose of this study was, to asses of choline/water ratio by usingmagnetic resonance spectroscopy (MRS) as an early predictive factor of cytostatics response after neoadjuvant therapy in breast cancer patients, secondly to analyze the correlation between external choline/water ratio and internal choline/water ratio.Material and method: This study was conducted at Cipto Mangunkusumo National General Hospital since August 2011 to April 2014. Subjects received cytostatics as neoadjuvant chemotherapy underwent MRI/MRS prior to cytostatics I, 20/21 days after having cytostatics I and after cytostatics III. MRI 1.5 T was used for MRI examination and syngo-GRACE program for MRS. Tumor measurement was based on RECIST 1.1, tumor response of ≥ 30% is considered positive, and < 30% is considered negative.Results: Among 40 non-ulcerating breast cancer subjects with tumor size of more or equal to 5 cm, 47.5% show positive response. MRS I and II showed escalation of external choline/water ratio on days 20/21 after the introduction of cytostatic I as neoadjuvant treatment, which could be used to predict tumor shrinkage after cytostatic III as high as 30% or more, RR = 0.49 (CI 0.26 - 0.90), especially for < IIIC stage. Changes of internal choline/water ratio, RR= 0.54 (CI 0.28 - 1.04) and Apparent Diffusion Coefficient (ADC) changes, RR= 0.51 (CI 0.23-1.13) show similar result but less related. A positive moderate correlation between changes of external choline/water ratio and changes of internal choline/water ratio is seen (r=0,572, p=0,000). No correlation between degree of malignancy, Bcl2, Ki67 dan MVD with tumor response. Changes of choline/water ratio combined with Ki67 higher than or equal with 14% could give positive tumor response, on the other hand, declining of choline/water ratio combined with Ki67 less than 14%, no positive tumor response could be found. Conclusion: Increased of external choline/water ratio on MRS I-MRS II on day 20 or 21 following cytostatic 1 as neoadjuvant chemotherapy can predict tumor shrinkage following cytostatic III of equal or more than 30%, especiallyfor < IIIC stage. Changes of external and internal choline/water ratio could be used to predict tumor response following cytostastic administration., Background : Cytostatics administration as neoadjuvant chemotherapy does not provided satisfactory tumor response in breast cancer patients and could be asses after 3rd cycle. To minimize the side effects and cost of cytostatics, early predictive factor of tumor response following neoadjuvant therapy in breast cancer patients is required. Objectives: The purpose of this study was, to asses of choline/water ratio by usingmagnetic resonance spectroscopy (MRS) as an early predictive factor of cytostatics response after neoadjuvant therapy in breast cancer patients, secondly to analyze the correlation between external choline/water ratio and internal choline/water ratio.Material and method: This study was conducted at Cipto Mangunkusumo National General Hospital since August 2011 to April 2014. Subjects received cytostatics as neoadjuvant chemotherapy underwent MRI/MRS prior to cytostatics I, 20/21 days after having cytostatics I and after cytostatics III. MRI 1.5 T was used for MRI examination and syngo-GRACE program for MRS. Tumor measurement was based on RECIST 1.1, tumor response of ≥ 30% is considered positive, and < 30% is considered negative.Results: Among 40 non-ulcerating breast cancer subjects with tumor size of more or equal to 5 cm, 47.5% show positive response. MRS I and II showed escalation of external choline/water ratio on days 20/21 after the introduction of cytostatic I as neoadjuvant treatment, which could be used to predict tumor shrinkage after cytostatic III as high as 30% or more, RR = 0.49 (CI 0.26 - 0.90), especially for < IIIC stage. Changes of internal choline/water ratio, RR= 0.54 (CI 0.28 - 1.04) and Apparent Diffusion Coefficient (ADC) changes, RR= 0.51 (CI 0.23-1.13) show similar result but less related. A positive moderate correlation between changes of external choline/water ratio and changes of internal choline/water ratio is seen (r=0,572, p=0,000). No correlation between degree of malignancy, Bcl2, Ki67 dan MVD with tumor response. Changes of choline/water ratio combined with Ki67 higher than or equal with 14% could give positive tumor response, on the other hand, declining of choline/water ratio combined with Ki67 less than 14%, no positive tumor response could be found. Conclusion: Increased of external choline/water ratio on MRS I-MRS II on day 20 or 21 following cytostatic 1 as neoadjuvant chemotherapy can predict tumor shrinkage following cytostatic III of equal or more than 30%, especiallyfor < IIIC stage. Changes of external and internal choline/water ratio could be used to predict tumor response following cytostastic administration.]"

"Latar belakang: Osteosarkoma merupakan tumor tulang primer ganas tersering yang ditemukan pada anak-anak dan remaja dengan prevalensi mencapai 20% dari seluruh keganasan tulang. Sejak pengenalan kemoterapi neoadjuvan, angka sintasan penderita osteosarkoma meningkat pesat menjadi 50-75%. Respons kemoterapi neoadjuvan selama ini dinilai secara histopatologik melalui operasi, dengan mengevaluasi persentase area nekrosis dibandingkan tumor. Sekuens diffusion weighted imaging (DWI) dan nilai apparent diffusion coefficient (ADC) adalah sekuens magnetic resonance imaging (MRI) untuk menilai restriksi difusi suatu jaringan secara kualitatif dan kuantitatif. Tujuan: Penelitian ini bertujuan mencari korelasi nilai ADC tumor pasca kemoterapi dengan pemeriksaan histopatologik untuk mengevaluasi respons kemoterapi neoadjuvan pada pasien osteosarkoma. Metode: Pengukuran nilai ADC tumor pada bagian mid, proksimal, dan distal pada MRI pasca kemoterapi neoadjuvan dengan menggunakan freehand range of interest (ROI) pada sekuens DWI dan ADC dengan nilai b 800. Freehand ROI diukur dengan melibatkan jaringan tumor dan nekrotik tanpa jaringan normal. Nilai ADC tersebut dikorelasikan dengan hasil persentase nekrosis dari pemeriksaan histopatologik berdasarkan lokasi sesuai potongan MRI dan laporan hasil operasi yang berupa persentase nekrosis keseluruhan. Analisis dilakukan dengan uji Pearson pada distribusi normal dan uji Spearman pada distribusi tidak normal. Hasil: Pada penelitian ini didapatkan 14 subyek penelitian dengan rerata nilai ADC tumor bagian proksimal sebesar 1,66±0,36x10-3 mm2/s, bagian mid 1,68±0,32x10-3 mm2/s, bagian distal 1,66±0,34x10-3 mm2/s, dan rerata ketiganya 1,67±0,32x10-3 mm2/s. Sedangkan persentase nekrosis keseluruhan sebesar 62,8±26,1%. Nilai ADC tumor bagian proksimal berkorelasi signifikan (p>0,05) dengan persentase nekrosis keseluruhan dengan nilai r sebesar 0,60. Luas penampang tumor pada bagian proksimal mempunyai ukuran yang paling kecil dibandingkan pada bagian mid dan distal. Kesimpulan: Dari penelitian ini disimpulkan bahwa nilai ADC tumor bagian proksimal pada MRI pasca kemoterapi dan ukuran luas penampang tumor yang kecil berkorelasi dengan respons kemoterapi neoadjuvan pada pasien osteosarkoma.

---

Background: Osteosarcoma is the most prevalent bone malignancy in children and adolescents, approximately 20% of all bone malignancies. Since the introduction of neoadjuvant chemotherapy, prognosis of osteosarcoma have been improved drastically to 50-75%. Neoadjuvant chemotherapy response has been assessed histopathologically after tumor resection, by calculating percentage of necrotic areas compared to tumor areas. Diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) value are magnetic resonance imaging (MRI) sequences to evaluate diffusion restriction in a tissue qualitatively and quantitatively.

Objective: The aim of this study was to seek correlation of post-chemotherapy tumor ADC value and histopathological assessment to evaluate neoadjuvant chemotherapy response in osteosarcoma patients.

Methods: ADC measurement was done in the proximal, middle, and distal part of the tumor by drawing freehand range of interest (ROI) guided by DWI sequence with b value of 800. The freehand ROI was drawn involving the tumor and necrotic area, excluding the normal ones. ADC value was correlated with necrotic percentage in each location according to MRI slices and necrotic percentage of the whole tumor based on the official report. Statistically, the data were analyzed with Pearson’s correlation (in normal distribution data) and Spearman correlation (in abnormal distribution).

Results: There were 14 subjects in this study, with ADC value of 1,66±0,36x10-3 mm2/s (proximal), 1,68±0,32x103 mm2/s (middle), 1,66±0,34x10-3 mm2/s (distal), and mean ADC value of 1,67±0,32x10-3 mm2/s. The necrotic percentage of the whole tumor was 62,8±26,1%. ADC value of proximal part of the tumor correlates significantly (p>0,05) with the necrotic percentage of the whole tumor (r = 0,60). Tumor area in the proximal part was smallest in size than other parts of the tumor.

Conclusion: From this study, it is concluded that ADC value in the proximal part of the tumor in post-chemotherapy MRI and lesser tumor size correlate to neoadjuvant chemotherapy response in osteosarcoma patients. "

"Identifikasi dini respons kemoterapi neoajuvan merupakan hal penting dalam tatalaksana kanker payudara. Penelitian bertujuan untuk mengetahui korelasi antara nilai microvessel density (MVD) prekemoterapi dengan perubahan apparent diffusion coefficient (ADC) pada magnetic resonance imaging (MRI) dan perubahan ukuran tumor pasca kemoterapi neoajuvan.Penelitian ini menggunakan desain potong lintang terhadap 16 pasien kanker payudara yang mendapat kemoterapi neoajuvan. Analisis bivariat menggunakan korelasi Pearson dengan (α)5%.Hasil penelitian menunjukkan tidak terdapatnya korelasi bermakna antara nilai MVD prekemoterapi dengan perubahan ADC maupun dengan perubahan ukuran pasca kemoterapi neoajuvan. Diperoleh kesimpulan bahwa MVD prekemoterapi tidak dapat memprediksi perubahan ADC maupun perubahan ukuran pasca kemoterapi neoajuvan.

---

Early identification in neoajuvant chemotherapy response is important in the treatment of breast cancer. The purpose of this study was to determine the correlation between microvessel density (MVD) before chemoterapy with changes in apparent diffusion coefficient (ADC) in magnetic resonance imaging (MRI) and changes in tumor size after neoajuvant chemotherapy.This study used a cross-sectional design of 16 breast cancer patients who received neoajuvant chemotherapy. Performed bivariate analysis using Pearson correlation ( α 5%).There was no significant correlation between MVD value with ADC changes as well as with changes in size after neoajuvant chemotherapy. It concluded that MVD value can not predict ADC changes after neoajuvant chemotherapy nor changes in size after neoajuvant chemotherapy."

"Kanker nasofaring merupakan jenis kanker yang biasa terjadi di Asia Tenggara dan angka kematiannya masih tinggi. Berdasarkan penelitian sebelumnya di dunia, survival pasien kanker nasofaring masih kurang dari 80%. Di Rumah Sakit Kanker Dharmais, kanker nasofaring merupakan 10 besar penyakit dengan kasus tertinggi stadium III. Desain studi ini bertujuan untuk mengetahui survival pasien kanker nasofaring berdasarkan respon tumor yang menjalani kemoterapi neoadjuvant dilanjutkan dengan kemoradiasi dan faktor prognostik yang mempengaruhinya. Total 261 pasien yang didapat antara bulan Januari 2009-Desember 2013 dianalisis secara retrospektif. Angka respon tumor pasien dengan CR (complete response), PR (partial response) and PD (progressive disease) adalah 33.7%, 45.2% dan 21.2%. Overall survival (OS) selama 5 tahun sebesar 38.6%. Angka OS pasien 5 tahun berdasarkan respon tumor CR, PR dan PD adalah 71.0%, 30.4% dan 10.6%. Variabel independen faktor prognostik yang signifikan adalah respon tumor, pendidikan, pekerjaan, riwayat minum alkohol, stadium dan ketepatan waktu pengobatan. Probabilitas pasien kanker nasofaring yang menjalani kemoterapi neoadjuvant dilanjutkan kemoradiasi dengan respon tumor CR lebih tinggi dibandingkan dengan PR dan PD. Deteksi dini dapat meningkatkan survival pasien dan penambahan jumlah sampel diperlukan untuk mendapatkan hasil yang lebih baik.

---

Nasopharyngeal cancer is a common malignancy in Southeast Asia with high mortality >rate. The previous studies showed that the patient survival rate are less than 80% worldwide. In Dharmais Cancer Hospital, nasopharyngeal carcinoma is in the top of 10 diseases with the highest case of stadium III cancer progression. The aim of this study is to determine the survival rate of nasopharyngeal carcinoma patients on the tumor response after receiving neoadjuvant chemotherapy followed by chemoradiation and their prognostic factors. A total of 261 patients referred between January 2009-December 2013 were restrospectively analyzed. Tumor response rate for patients with CR (complete response), PR (partial response) and PD (progressive disease) were 33.7%, 45.2% and 21.2% respectively. The 5-years survival rate on tumor response among CR, PR and PD were 71.0%, 30.4% and 10.6% respectively. The significant independent prognostic factors are tumor response, education backgrounds, jobs, alcohol consumption, stadium of cancer and prompt treatment. The probability of nasopharyngeal cancer patients receiving neoadjuvant chemotherapy followed by chemoradiation is higher to CR than PR and PD. Therefore, early detection could improve patients survival and more sample increased the result in this study."

"Latar Belakang: NAC neoadjuvant chemotherapy secara umum telah digunakan di LABC locally advanced breast cancer untuk mengurangi ukuran tumor dan membuat tumor tersebut bisa untuk dioperasi. Meskipun ukuran tumor telah berkurang, masih diperdebatkan batas pembedahan pasca NAC untuk LABC dengan karsinoma mastitis, ulkus payudara, dan fitur agresif lainnya bebas dari tumor karena kemoterapi tidak bisa membunuh 100 dari sel-sel tumor. Metode: Desain penelitian adalah studi potong lintang. Sampel diambil dari semua pasien dengan LABC yang datang ke klinik onkologi rawat jalan dari RS Cipto Mangunkusumo dan ditato untuk batas pembedahan berdasarkan ukuran tumor sebelum NAC. Penelitian ini dilakukan untuk menentukan batas pembedahan yang benar di LABC setelah NAC. Hasil: Dari total 85 pasien, 42 pasien termasuk dalam studi dan 30 pasien masih menjalani pemberian NAC. Umur pasien berkisar antara 27-70 tahun dengan frekuensi tertinggi adalah 40-50 tahun 47,6 . Frekuensi kasus tersering adalah pasien dengan stadium IIIB 92,9 , grade 2 66,7 , histopalogi karsinoma duktal invasif 92,8 hasil IHK imunohistokimia over-ekspresi HER2 42,8 , volume tumor sebelum NAC > 100cc 85,8 dan volume tumor setelah NAC 50-100cc 57,2 . Regimen kemoterapi yang banyak digunakan CAF 76,1 dengan respon parsial 95,2. Kesimpulan: Batas sayatan kulit berdasarkan ukuran tumor pasca NAC dapat menjadi acuan untuk operasi, namun pada dasar sayatan operasi masih perlu dilakukan frozen section untuk memastikan bebas tumor atau tidak. Seorang ahli bedah juga harus lebih berhati-hati dalam menentukan batas sayatan operasi pada kasus mastitis karsinomatosis, ulkus payudara yang besar dan tumor yang terletak di medial payudara dimana pada kondisi ini batas sayatan operasi dapat beresiko tidak bebas tumor.

---

Introduction: There is limited evidence regarding the effectivness of neoadjuvant chemotherapy NAC to improve surgical margins for locally advanced breast cancer LABC patients. In this study, NAC was used to reduce tumor size to improve operability and reduce surgical margins, with confirmation of tumor free areas provided by post operative histopathology. The reduction of surgical margins has the potential to reduce the need for extensive surgery and the risk of complications in LABC patients.

Method: The study participants were patients diagnosed with LABC in Ciptomangunkusumo Hospital Jakarta and Awal Bros Bekasi Hospital Bekasi between 2014 and 2015. Patients underwent NAC, and those with partial or complete response were sent for surgery. Tumor excision was done according to the pre NAC surgical margin, which was marked by tattoo. Histopathology then checked for tumor cells in the surgical margins based on breast tumor size of pre and post NAC. Data was analyzed with SPSS version 20 with numerous statistical tests. Cross tabulation analyses were done to examine the characteristics of the study participants. McNemar test was used to determine and compare the pre and post NAC surgical margins.

Results: Out of 42 patients, 38 were observed to have tumor free surgical margins in both pre and post NAC. Of the remaining four patients, three patients had tumor cells in both surgical margins, and one patient had a tumor free pre NAC but positive tumor cells post NAC. McNemar analysis suggests no significant difference p 1,000 in the two surgical margins evaluated. Based on Wilson score analysis, agreement of negative result of surgical margin in pre NAC compare to post NAC is 97.3 CI 86,18 99.52 . Mean while, agreement of positive tumor cell in pre NAC to post NAC surgical margin is 100 CI 90.36 100.

Conclusion: Surgical margins in the skin based on the post NAC tumor size can be used as a guide for surgery, but not in the tumor base. If the surgical margin of tumor base is ambiguos, frozen section can be performed to confirm tumor free in the tumor base. This will reduce the risk of residual tumor cells in surgical margins. "

"Kanker payudara merupakan salah satu masalah kesehatan terbesar di Indonesia di mana sekitar 42,7% datang pada stadium lanjut lokal. Pemberian kemoterapi neoajuvan pada stadium lanjut lokal bertujuan mengecilkan ukuran tumor sehingga dapat dilakukan operasi dan menurunkan mortalitas. Salah satu prediktor untuk mengetahui keberhasilan kemoterapi neoajuvan adalah Ki-67, yaitu protein non-histone yang ekspresinya tinggi saat proliferasi sementara obat-obatan kemoterapi bekerja efektif pada fase proliferasi. Tujuan penelitian ini adalah untuk mengetahui peran Ki-67 sebagai faktor prediktor terhadap respons kemoterapi neoajuvan pada pasien KPDLL. Metode: Penelitian ini merupakan studi kohort retrospektif dengan kriteria inklusi adalah pasien dengan diagnosis kanker payudara stadium lanjut lokal dan mendapatkan kemoterapi neoajuvan di Rumah Sakit Cipto Mangunkusumo (RSCM) sejak 1 Januari 2014- 31Desember 2019. Cut-off ekspresi Ki-67 adalah 20%. Respons klinis kemoterapi neoajuvan dinilai berdasarkan kriteria WHO yang diukur setelah pemberian kemoterapi ketiga. Respons kemoterapi ini dikelompokkan menjadi respons baik (complete response dan partial response) dan respons buruk (stable disease dan progresive response). Hasil: Pasien kanker payudara lanjut lokal rata-rata berusia 50 tahun, ukuran tumor terbanyak T4 (90,4%), keterlibatan kelenjar getah bening N1 (52,1%), jenis histopatologi NST (71,3%), grade 2 (54,4%), ER positif (78,7%), PR positif (70,2%), HER2negatif (58,5%), Ki67 tinggi (70,2%), dan luminal B (56,4%). Lima puluh dua koma satu persen subjek memiliki respons kemoterapi buruk. Tidak terdapat perbedaan bermakna secara statistik antara ekspresi Ki-67 dengan respons kemoterapi (p= 1). Bila dihitung presentase sisa tumor, pasien dengan ekspresi Ki-67 tinggi memiliki persentase sisa tumor 74,6%, pasien dengan ekspresi Ki-67 rendah rata-rata tidak mengalami penurunan ukuran tumor dengan sisa tumor 103,8% (p= 0,977). Simpulan: Tidak terdapat perbedaan bermakna secara statistik antara ekspresi Ki-67 dan respons kemoterapi neoajuvan pada kanker payudara stadium lanjut lokal di RSCM.

---

Breast cancer is one of the most common health problems in Indonesia where 42.7% of patients have been diagnosed with Locally Advanced Breast Cancer (LABC). Neoadjuvant chemotherapy (NAC) is aimed to decrease the tumor size to be operable and decrease mortality. Ki-67 is highly expressed in the cell proliferation phase, while chemotherapy agents work effectively by targeting this proliferation. This study evaluates the utility of Ki-67 in LABC patients of the Asian-Indonesian population. Methods: This is a retrospective cohort study. Ki-67 data was from the medical record based on the immunohistochemistry staining with >20% cut off point. Clinical response was measured based on the WHO criteria after the third chemotherapy cycle, classified as good response (complete response and partial response) and poor response (stable disease and progresive response). Result: The majority of subjects in this study were 50 years old, with T4 tumor size (90.4%), N1 lymph node involvement (52.1%), NST histopathological type (71.3%), grade 2 (54.4%), ER-positive (78.7%), PR-positive (70.2%), HER2-negative (58.5%), high Ki67 expression (70.2%), and luminal B subtype (56.4%). 52.1% of all subjects showed ‘poor’ clinical responses to NAC. There was no significant association between subjects’ characteristics and the NAC Clinical response. Moreover, there was no significant association between Ki-67 and chemotherapy clinical response (p=1). Residual tumor size was 74.6% in high Ki-67 group and 103.8% in low Ki-67 group (p= 0.977). Conclusion: There is no statistically significant association between Ki-67 expression and NAC clinical response of LABC patients in Indonesia."

"Measurement of solid tumor response to treatment relies mainly on imaging. WHO tumor response criteria and, more recently, RECIST (response evaluation criteria in solid tumors) have provided means to objectively measure tumor response in clinical trials with imaging. These guidelines have been rapidly adopted in clinical practice to monitor patient treatment and for therapy planning. However, relying only on anatomical information is not always sufficient when evaluating new drugs that will reduce a tumor's functionality while preserving its size. Finding more reliable and reproducible measures of tumor response is one of the most important and difficult challenges facing modern radiology as it requires an entirely new approach to imaging. The aim of this book is to address the assessment of response to treatment by adopting a multidisciplinary perspective, just as occurs in real life in a comprehensive cancer center. Oncologists and imaging experts consider two cancer models, locally advanced disease and metastatic disease, jointly exploring both conventional and advanced means of measuring response to standard treatment protocols and new targeted therapies."